Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model

Overview of attention for article published in JAMA Oncology, July 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 17 news outlets
blogs: 7 blogs
policy: 1 policy source

twitter: 196 X users
facebook: 3 Facebook pages
googleplus: 2 Google+ users

Citations

dimensions_citation: 221 Dimensions

Readers on

mendeley: 288 Mendeley

Summary News Blogs Policy documents X Facebook Google+ Dimensions citations

So far, Dimensions has found 221 publications that cite this research output.

221

The most recent citing publications are shown below. View all 221 publications that cite this research output on Dimensions.

The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families

Article in The Breast (June 2024)

Functional partial least squares with censored outcomes: Prediction of breast cancer risk with mammogram images

Article in The Annals of Applied Statistics (June 2024)

A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening

Article in Applied Health Economics and Health Policy (May 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.